



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### **ALPK1 hotspot mutation as a driver of human spiradenoma and spiradenocarcinoma**

**Citation for published version:**

Rashid, M, van der Horst, M, Mentzel, T, Butera, F, Ferreira, I, Pance, A, Rütten, A, Luzar, B, Marusic, Z, de Saint Aubain, N, Ko, JS, Billings, SD, Chen, S, Abi-Daoud, M, Hewinson, J, Louzada, S, Harms, PW, Cerretelli, G, Robles-Espinoza, CD, Patel, RM, van der Weyden, L, Bakal, C, Hornick, JL, Arends, MJ, Brenn, T & Adams, DJ 2019, 'ALPK1 hotspot mutation as a driver of human spiradenoma and spiradenocarcinoma', *Nature Communications*, vol. 10, 2213. <https://doi.org/10.1038/s41467-019-09979-0>

**Digital Object Identifier (DOI):**

[10.1038/s41467-019-09979-0](https://doi.org/10.1038/s41467-019-09979-0)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Nature Communications

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



***ALPK1 hotspot mutation as a driver of human spiradenoma and spiradenocarcinoma***

Mamunur Rashid<sup>1\*</sup>, Michiel van der Horst<sup>2\*</sup>, Thomas Mentzel<sup>3</sup>, Francesca Butera<sup>4</sup>, Ingrid Ferreira<sup>1</sup>, Alena Pance<sup>1</sup>, Arno Rütten<sup>3</sup>, Bostjan Luzar<sup>5</sup>, Zlatko Marusic<sup>6</sup>, Nicolas de Saint Aubain<sup>7</sup>, Jennifer S. Ko<sup>8</sup>, Steve D. Billings<sup>8</sup>, Sofia Chen<sup>1</sup>, Marie Abi Daoud<sup>9</sup>, James Hewinson<sup>1</sup>, Sandra Louzada<sup>1</sup>, Paul W. Harms<sup>10</sup>, Guia Cerretelli<sup>11</sup>, Carla Daniela Robles-Espinoza<sup>1,12</sup>, Rajiv M. Patel<sup>10</sup>, Louise van der Weyden<sup>1</sup>, Chris Bakal<sup>4</sup>, Jason L. Hornick<sup>13</sup>, Mark J. Arends<sup>11</sup>, Thomas Brenn<sup>9,11×</sup>, David J. Adams<sup>1×</sup>.

\*These authors contributed equally. × These authors jointly supervised the work.

<sup>1</sup>Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, CB10 1SA. UK.

<sup>2</sup>Department of Pathology, Maastad Hospital, Maastadweg 21, Rotterdam, 3079 DZ, The Netherlands.

<sup>3</sup>Dermatopathologie Friedrichshafen. Siemensstrasse 6/1, 88048 Friedrichshafen, Germany.

<sup>4</sup>Dynamical Cell Systems Laboratory. Chester Beatty Laboratories, Division of Cancer Biology. Institute of Cancer Research. London, SW3 6JB. UK

<sup>5</sup>Institute of Pathology, Medical Faculty University of Ljubljana, Korytkova 2, Ljubljana 1000, Slovenia.

<sup>6</sup>University Hospital Center Zagreb, Kispaticeva 12. 10 000 Zagreb. Croatia.

<sup>7</sup>Institute Jules Bordet. Institut Jules Bordet: 121-125, boulevard de Waterloo – 1000 Brussels, Belgium.

<sup>8</sup>Department of Pathology. Cleveland Clinic. Cleveland, OH 44195. USA.

<sup>9</sup>Departments of Pathology & Laboratory Medicine and Medicine and The Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, T2L 2K8, Canada.

<sup>10</sup>Departments of Pathology and Dermatology, University of Michigan Medical School, 2800 Plymouth Road, Ann Arbor, Michigan 48109-5602, USA.

<sup>11</sup>Division of Pathology, Cancer Research UK Edinburgh Centre, The University of Edinburgh, Institute of Genetics & Molecular Medicine, Crewe Road, Edinburgh, EH4 2XR, UK.

<sup>12</sup>Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Blvd Juriquilla 3001, Santiago de Querétaro, 76230, Mexico.

<sup>13</sup>Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

***Address for correspondence:***

Dr. David Adams

da1@sanger.ac.uk

Ph: +44 (0) 1223 496862

## Abstract

Spiradenoma and cylindroma are distinctive skin adnexal tumors with sweat gland differentiation and potential for malignant transformation and aggressive behaviour. We present the genomic analysis of 75 samples from 57 representative patients including 15 cylindromas, 17 spiradenomas, 2 cylindroma-spiradenoma hybrid tumors, and 24 low- and high-grade spiradenocarcinoma cases, together with morphologically benign precursor regions of these cancers. We reveal somatic or germline alterations of the *CYLD* gene in 15/15 cylindromas and 5/17 spiradenomas, yet only 2/24 spiradenocarcinomas. Notably, we find a recurrent missense mutation (22 tumors, 18 patients) in the kinase domain of the *ALPK1* gene in spiradenomas and spiradenocarcinomas, which is mutually exclusive from mutation of *CYLD* and can activate the NF- $\kappa$ B pathway in reporter assays. In addition, we show that high-grade spiradenocarcinomas carry loss-of-function *TP53* mutations, while cylindromas may have disruptive mutations in *DNMT3A*. Thus, we reveal the genetic landscape of adnexal tumors and therapeutic targets.

## Introduction

There are two main groups of adnexal tumors; those that are associated with the female reproductive system including tissues such as the ovaries, fallopian tubes and the connective tissues that surround these structures, and skin adnexal tumors of cutaneous origin. The word “adnexa” is Latin in origin and refers to the appendages of an organ. Spiradenoma and cylindroma are closely related benign skin adnexal tumors with sweat gland differentiation. They show histological similarities and may represent part of a morphological spectrum, further evidenced by rare spiradenoma-cylindroma hybrid tumors. The majority of tumors are sporadic and present as solitary nodules. Spiradenomas show a predilection for the extremities, while cylindromas commonly occur on the head and neck<sup>1</sup>. Occasionally, they may be multiple in the setting of the Brooke-Spiegler syndrome (BSS), a rare autosomal-dominant inherited disorder characterized by cylindromas, spiradenomas and/or trichoepitheliomas in individuals with germline mutation of the *CYLD* gene<sup>2</sup>. Malignant transformation in spiradenoma (spiradenocarcinoma) and, less frequently, cylindroma (cylindrocarcinoma) is a rare event. Histologically these tumors are composed of a benign precursor and a morphologically distinct malignant component, which may be further subdivided into low-grade or high-grade<sup>3</sup>. The morphology of these tumors appears to be a good predictor of outcome. Morphologically low-grade tumors have potential for local recurrence, while disseminated disease and disease-related mortality is largely limited to high-grade carcinomas<sup>3, 4, 5, 6</sup>. Little is known about the underlying genetic events that drive these tumors. Cylindromas are characterized by mutations in *CYLD* and approximately two thirds of sporadic cylindromas have also been reported to carry the *MYB-NFIB* fusion gene, which leads to overexpression of MYB, analogous to adenoid cystic carcinoma<sup>7, 8, 9</sup>. No genetic data are available for spiradenomas and the events leading to malignant transformation and to the more aggressive behavior of the high-grade tumors are largely unknown. As yet, only mutations in the *TP53* gene have been reported in the malignant tumors<sup>10, 11</sup>.

To improve understanding of these rare diseases we perform a comprehensive genomic characterisation of samples from a large collection of representative patients and detail the driver gene landscape and biological processes that are operative. Notably, we find a hotspot driver mutation in *ALPK1* that defines spiradenoma and spiradenocarcinoma cases.

## Results

### Sample ascertainment and whole exome sequencing

Samples were obtained through the University of Edinburgh Tissue Bank with ethical approval obtained under REC 15/ES/0094. Analysis of these samples was also approved by the Sanger Human Materials and

Data Management Committee (HMDMC). Cases were independently reviewed by two dermatopathologists to confirm diagnoses. In total 75 samples underwent next-generation sequencing, 52 with paired adjacent normal/germline DNA (from 42 patients), while the remaining 23 samples (15 patients) without matched normal/germline DNA were used as a validation cohort (**Supplementary Data 1**). Capillary sequencing was also performed on 10 cases from 10 additional patients to validate a hotspot mutation as described below. A full breakdown of the samples used at the various stages of analysis and available clinical characteristics of each patient is provided in **Supplementary Data 1**. Briefly, high- and low-grade spiradenocarcinoma, benign spiradenoma and dermal cylindroma patients had a median age of 72.5, 61.5, 58 and 60 years at diagnosis, respectively. Notably, four patients (one cylindroma, one spiradenoma, one patient with a high-grade spiradenocarcinoma and a patient with both a cylindroma-spiradenoma hybrid hybrid tumour and a high-grade spiradenocarcinoma) were previously diagnosed with Brooke-Spiegler syndrome. Half of tumors (37/68; 54%) were located on the head and neck area while the remaining cases were from the trunk (19/68; 28%) or extremities (7/68; 10%). The tissue sites for the remaining 8% of tumors (5/68) were unknown. Formalin-fixed paraffin-embedded (FFPE) cores were collected from each tumor and DNA extracted, while uninvolved adjacent skin (epidermis/dermis/superficial subcutis) was used to obtain normal/germline DNA where available (referred to here as adjacent normal/germline). For several spiradenocarcinomas we analysed both low- and high-grade regions (**Supplementary Data 1**). DNA samples were whole-exome sequenced on the Agilent/Illumina platform at the Wellcome Trust Sanger Institute generating a median depth of 60x coverage (after duplicate removal and read clipping).

### **The somatic mutational landscape of adnexal tumors**

DNA sequencing data from the 52 tumor/germline pairs was subjected to somatic variant calling (see **Methods**) resulting in the identification of 1124 somatic point mutations in exons of which 817 were protein altering and 307 were silent mutations. The number of somatic single nucleotide variants (SNVs) varied markedly between individual tumor samples (mean 21.6 mutations, range 2-144) (**Fig. 1, Supplementary Data 2**). In addition to SNVs, we also called 219 small insertion/deletions (indels) (**Supplementary Data 2**). Recurrently altered cancer driver genes included *CYLD* (14 cases), *NRAS* (*p.Q129E*, *p.Q61K* in the same sample), *AKT1* (*p.E17K* in three cases), *TP53* (*p.E286K*, *p.G266E*, *p.R248Q* and indels *p.D228Fs\*20*, *p.R209Fs\*6*) and *DNMT3A* (*p.R556M*, *p.R320\**, *E213\_splice*, *E585\_splice*)(**Fig. 1**). All mutations shown were validated using high-depth (median depth of coverage 117x) targeted exome capture across all samples where DNA was available (Agilent design ID: S3065404) (**Supplementary Data 1**). To further validate our variant calls and to determine the accuracy of our whole-exome sequence capture analysis, we used our targeted exome data to assay a further 119 randomly selected somatic variants revealing an overall validation rate of 82%. For indels the validation rate was 73%. A pan-cancer analysis revealed that in

comparison to cancers sequenced by The Cancer Genome Atlas (TCGA), the tumors sequenced here have a low somatic point mutation burden in the exome and fall within the range of 0.04-2.88 mutations/Mb (**Supplementary Fig. 1**), a frequency similar to thyroid cancer and uveal melanoma. Generally, cylindromas were found to carry more mutations than the other tumor types (Wilcoxon test  $P = 0.0153$ ). Potential associations between the number of somatic mutations and age, sex of the patient, and tumor site were examined using a generalised linear model. No significant relationships with any individual clinical feature were observed. An overview of the genomic landscape including all available clinical characteristics for these cases can be found in **Supplementary Fig. 2**.

### **Identification of driver genes in adnexal tumors**

A typical tumor cell may contain tens to thousands of somatic mutations distributed across hundreds of genes. Only a handful of these genes when mutated confer a selective growth advantage and thus may facilitate the promotion of tumor growth<sup>12</sup>. We applied two independent driver gene discovery tools: IntOGen and dNdScv to detect potential driver genes in our adnexal tumor cohort<sup>13, 14</sup>. The IntOGen driver gene prioritization framework combines scores from SIFT, PolyPhen2 (PPH2) and MutationAssessor (MA), to calculate the functional impact bias (FM bias) of mutations in genes against a background distribution<sup>13, 15, 16, 17</sup>. Using this approach genes computed to have a significant functional impact score (OncodriverFM q value) are reported as drivers. dNdScv on the other hand is a maximum likelihood-based method used to quantify positive selection of genes mutated in cancer using the ratios of missense and disruptive mutations vs synonymous mutations. We performed driver gene analyses using both of the aforementioned workflows using somatic mutations from the cylindromas, spiradenomas and high-grade and low-grade spiradenocarcinomas. A consensus of these two approaches is reported here. *CYLD* and *DNMT3A* were identified as statistically significant driver genes in cylindroma. *CYLD* was also reported as a driver gene in spiradenoma, while the tumor suppressor gene *TP53* was found to be significantly enriched with mutations in high-grade spiradenocarcinoma. Notably, *ALPK1* was recurrently mutated at a hotspot position and was reported as a driver event in both spiradenoma (both methods) and spiradenocarcinoma (only by IntOGen), and is discussed in detail below. This mutation was absent from cylindromas. A complete list of the driver genes and significance values for each adnexal tumor type can be found in **Supplementary Data 3**. This table also provides the aggregate number of missense, nonsense and synonymous mutations identified in each gene.

### **A recurrent *ALPK1* mutation in spiradenoma and spiradenocarcinoma**

The *ALPK1* ( $\alpha$ -kinase 1) gene is a member of the  $\alpha$ -kinase family and is located on chromosome 4q25<sup>18</sup>. Recent studies have indicated that the expression of *ALPK1* during infection/inflammation can result in the

activation of nuclear factor-kappa-B (NF- $\kappa$ B) signalling and downstream gene expression<sup>19, 20</sup>. Somatic mutation of *ALPK1* in 32/1397 lung cancer samples (2.29%) and 29/781 colorectal cancer samples (3.71%) has recently been reported<sup>18</sup> and *ALPK1* has been shown to function as an oncogene in oral squamous cancers<sup>21</sup>.

We discovered a recurrent somatic hotspot mutation in the alpha kinase domain of the *ALPK1* gene (p.V1092A) in 7/16 spiradenomas, 2/8 high-grade and 2/6 low-grade spiradenocarcinomas (**Fig. 1 & 2, Supplementary Data 2**) from our discovery cohort. All mutations were validated using targeted gene panel sequencing (see **Methods**). The hotspot mutation (p.V1092A) was also validated via Sanger sequencing in 8/11 of the aforementioned cases identified by whole exome sequencing. The position was also tested in 7 wildtype samples, all of which were confirmed to be mutation negative (**Supplementary Data 1**). Interestingly, in several cases (n=5) we observed the *ALPK1* p.V1092A mutation in the adjacent morphologically normal tissue (in addition to the tumor) from which the normal/germline DNA for somatic variant calling was extracted. The average mutant allele fraction of the mutation in these samples was 0.32 suggesting that they are clonal or present in a significant proportion of cells. None of the other somatic mutations in the corresponding tumor sample were found in the sequence data from the adjacent morphologically normal tissue making extensive tumor to normal contamination unlikely (see **Methods**). This mutation was also observed in sequence data generated from benign precursor regions (n=4) suggesting that the *ALPK1* p.V1092A mutation may be an early founder/truncal mutation, or is associated with a field change, as has been widely reported for other cancers, particularly skin<sup>22</sup>. Interestingly, mutation of *ALPK1* was mutually exclusive (q value 0.00146<sup>23</sup>) from mutation of *CYLD*<sup>22, 24</sup> (**Fig. 1**). To further confirm the presence of the *ALPK1* p.V1092A mutation a further 10 spiradenoma tumor/normal pairs were tested via Sanger sequencing and the p.V1092A mutation was observed in six tumors.

### **Mutation of *CYLD* in adnexal patients and tumors**

*CYLD* (CYLD Lysine 63 Deubiquitinase) encodes a cytoplasmic protein with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains and functions as a deubiquitinating enzyme and tumor suppressor<sup>25</sup>. *CYLD* regulates the NF- $\kappa$ B pathway, which plays important roles in cell growth and survival<sup>26, 27</sup>. Germline mutation of *CYLD* is associated with Brooke-Spiegler syndrome, which may present with cylindroma, cylindromatosis, trichoepithelioma and/or spiradenoma<sup>2</sup>. Eleven of the twelve cylindroma patients we sequenced carried either germline or somatic protein altering mutations of *CYLD*. The final cylindroma case (PD29703a) was found to carry a somatic splice region mutation (16: 50815325 A/G) located three bases away from the splice junction. *CYLD* mutations were also found in 31% (5/16) of the spiradenomas (**Fig. 1**). All four patients with a prior Brooke-Spiegler syndrome diagnosis whose germline

we sequenced carried a germline *CYLD* mutation. The protein altering mutations in *CYLD* are shown in **Fig. 2a**.

### **Promoter and regulatory mutations**

*Cis*- regulatory elements control the transcription of genes and mutations in these regions can potentially lead to aberrant protein production and tumorigenesis. Exome sequencing is not well equipped to detect *cis*- regulatory element mutations as it is designed to capture protein-coding regions. However, sufficient coverage (>10x read coverage) around exon boundaries allowed us to investigate the status of proximal regulatory elements such as promoters. Detected non-coding mutations were scored for pathogenicity weighting them with a CADD (Combined Annotation Dependent Depletion) variant deleteriousness score<sup>28</sup> (see **Methods**). Mutations were also annotated in the regulatory regions of known cancer driver genes. In this way, we identified mutations in the *TERT* promoter region (C228T and C250T) in four spiradenocarcinomas, known hotspot positions in other cancers<sup>29</sup>. Somatic mutations in the proximal regulatory regions of other genes such as *SPTA1*, *HMCN1* and *COL11A1* were also detected (**Supplementary Data 2**).

### **Mutational processes in adnexal tumors**

Somatic mutations in tumor cells may be the consequence of aberrant endogenous processes such as defective DNA repair or due to exogenous factors such as exposure to carcinogens. The imprint of a mutational process on DNA sequence is commonly referred to as a mutational signature<sup>30</sup>. Analysis of mutational signatures has led to a better understanding of the underlying biological processes associated with a number of cancers and has also allowed patient stratification for therapy<sup>31</sup>.

To assess the presence of published human cancer mutational signatures in the catalogue of somatic mutations from adnexal tumors we used deconstructSigs (see **Methods**)<sup>32</sup>. This approach computes the weighted contributions of the 30 published COSMIC signatures and one additional unknown signature to the mutational catalogue of each sample. The heatmap in **Fig. 3a** represents the contribution of these signatures across all adnexal tumor subtypes. In more than a quarter (26.92%) of tumors the contribution of signature 1 was greater than 0.5 meaning most mutations in these samples can be attributed to this signature. Signature 1, is an endogenous mutational process associated with spontaneous deamination of 5-methylcytosine, which is often correlated with age<sup>33</sup>. The mutation catalogue from cylindromas was also enriched for signature 7, which is predominantly found in skin cancers as a result of ultra violet (UV) light exposure. The predilection of cylindromas to form on the head and neck is likely to explain this signal. We also performed an analysis combining mutations for each tumor type together and again identified signature



1 and signature 7 in cylindromas, while several low-grade spiradenocarcinomas showed a signal for signature 26, which is thought to be associated with DNA mismatch repair<sup>30</sup>.

### **Somatic DNA copy number alterations**

The copy number status of our adnexal samples was assessed using Sequenza, an allele specific copy number analysis algorithm that uses matched tumor-normal pairs<sup>34</sup>. Sequenza reported a total of 1,577 somatic copy number changes (1,350 gains and 227 losses) across 52 tumors. Several high-grade spiradenocarcinomas showed large copy number changes, while low-grade spiradenocarcinomas demonstrated a comparably lower number of copy number events, although a larger number of samples will be required to fully explore the copy number landscape of these tumors. Cylindromas and spiradenomas generally showed few copy number changes, as did morphologically benign precursor regions. Genome-wide copy number profiles across all subtypes are reported in **Fig. 3b**.

### **The *MYB-NFIB* fusion in adnexal tumorigenesis**

A previous report has suggested a role for *MYB-NFIB* fusions in the pathogenesis of both adenoid cystic carcinoma and cylindroma<sup>8,9</sup>. Using dual-colour FISH we analysed 21 cases including 13 cylindromas, 7 spiradenomas and 1 cylindroma-spiradenoma hybrid tumor in addition to an adenoid cystic carcinoma case known to carry the *MYB-NFIB* fusion as a control. This analysis revealed that, despite previous reports, none of the cylindromas were found to carry the fusion event<sup>8</sup>. The *MYB-NFIB* fusion was also absent from the spiradenomas and cylindroma-spiradenoma hybrid tumor (**Fig. 4a-b, Supplementary Figs. 3 & 4**). Overexpression of MYB was, however, confirmed in cylindroma and spiradenoma cases using immunohistochemistry (**Fig. 1 & Supplementary Data 4**) suggesting other mechanisms of gene overexpression are operative.

### **Germline analysis of adnexal tumor patients**

As mentioned above, we identified germline *CYLD* mutations in all four patients previously diagnosed with Brooke-Spiegler syndrome. A germline *CYLD* mutation (in-frame deletion) was also detected in an additional patient with no prior Brooke-Spiegler syndrome diagnosis (PD29699) (**Fig. 1**). To extend the analysis of germline variation in patients from our cohort we used samtools mpileup and the bcftools variant genotyping strategy<sup>35</sup>. We assessed the coding mutation burden per gene using a Fisher's exact test (see **Methods**) (**Supplementary Data 2**)<sup>36</sup> using variants from the 42 cases where adjacent normal/germline exome sequence had been generated. From this analysis *CYLD* was found to carry significantly more mutations than expected (Benjamini-Hochberg (BH) adjusted *p*-value 0.01), reconfirming its well-established role as an adnexal tumor predisposition gene. We also detected a significantly high number of

mutations in *FAT4*, *BFAR*, *CRB2* and *PEX14* (BH adjusted *p*-value <0.05). *FAT4* is a member of human *FAT* gene family which encodes a large transmembrane protein consisting of multiple extracellular cadherin domains and a cytoplasmic domain that can interact with signalling molecules<sup>37</sup>. This gene is homologous to *fat* in *Drosophila*, a known tumor suppressor gene<sup>38</sup>. It should be noted, however, that *FAT4* has been reported as ‘disease-associated’ in several studies, which might suggest a high rate of polymorphism<sup>39, 40, 41</sup>. *BFAR*, the bifunctional apoptosis regulator, plays a role in the regulation of cell death and in this way could contribute to tumorigenesis<sup>42</sup>. Notably for *FAT4*, *BFAR*, *CRB2* and *PEX14* we did not identify somatic mutations in the wildtype allele of these genes in the cases carrying germline mutations suggesting that if they are contributing to tumor formation they most likely do not function as classical tumor suppressors. Further, samples with germline variants in these genes also had germline or somatic loss-of-function alleles of *CYLD*, making these less likely candidate predisposition genes. We next asked if mutations of known pathogenicity were found in the germline of any of our adnexal cases. In this way we found 14 pathogenic or likely pathogenic variants including missense mutations in *PTEN* and *NSDI* (**Supplementary Data 2**) (ClinVar database (dbSNP build 144)). The *PTEN* mutation we found has been reported in a single individual in ClinVar with a Cowden-like syndrome and changes a phenylalanine to a serine (P200S). This substitution occurs at a position that is conserved across species. *In silico* analysis predicts that this variant is probably damaging to protein structure/function. Missense (disease causing) mutations in nearby residues (V191G, M198K, T202I, M205V, S207R) have been reported, supporting the functional importance of this region of the protein. That said, the clinical records for our patient (PD29681) do not mention Cowden syndrome and the patient was 81 when their skin tumor was removed. Further, we did not detect a somatic mutation in the other allele of *PTEN*. In contrast our patient carrying a germline mutation in *NSDI* carries a well-established SOTO syndrome-associated allele (R2017W) predicted to be disruptive of SET domain function<sup>43, 44</sup>. Thus, of the 42 adnexal patients analysed here we have shown that five patients carry germline mutations in *CYLD* and propose several other candidate genes as mediators of germline susceptibility for follow-up studies.

### **Analysis of tumors without matched germline DNA**

For 52 of the samples in our cohort we had matched tumor/adjacent normal-germline pairs (as described above). Matched germline DNA was not available for a further 23 samples (15 patients; 3 cylindroma, 1 spiradenoma, 1 cylindroma-spiradenoma hybrid, 3 low-grade spiradenocarcinoma, 7 high-grade spiradenocarcinoma) and thus we used the tumor sequences from these cases as a validation cohort to look for variants in genes identified from the abovementioned analyses. We first called variants against an unmatched normal sample (**Supplementary Data 1**) and then filtered these data using variants in the ExAC database<sup>36</sup> (with an allele frequency > 0.0001) and with variants from an in-house panel of 100 normal

germline exomes. We next focused on genes identified from our analysis of the discovery cohort (see **Methods**) revealing *ALPK1* p.V1092A mutations in one cylindroma-spiradenoma hybrid, two low-grade spiradenocarcinomas and one spiradenoma. Loss-of-function mutations were also detected in *CYLD* in cylindroma cases (PD29695a, PD29696a, PD29700a) and in one low-grade spiradenocarcinoma (PD29676a). Tumors from two high-grade spiradenocarcinoma patients (PD29684, PD29685) were found to carry frameshift deletions in *TP53* (*p.P191fs\*54* and *p.T329fs\*8*). For each patient, the respective changes were present in all collected tumor samples indicating they maybe germline in origin or occur early in tumor development. An overview of the driver gene landscape and clinical characteristics of all 75 tumors/samples can be found in **Supplementary Fig. 5**.

### **Functional studies of the *ALPK1* p.V1092A variant**

Given the role of *ALPK1* in the regulation of the NF- $\kappa$ B pathway in infection we next asked if the *ALPK1* p.V1092A variant could activate NF- $\kappa$ B signalling and thus substitute for mutation of *CYLD*. To do this we generated full-length *ALPK1* wildtype and p.V1092A mutant cDNA constructs in an expression vector. Since adnexal cell lines do not exist we transfected these constructs into a panel of six NF- $\kappa$ B reporter cell lines (**Supplementary Fig. 6**). Analysis in this way showed that the mutant construct activated NF- $\kappa$ B reporter activity to a considerably higher level than the wildtype construct in MCF7, WM266-4 and WM1552C cells, consistent with a role for this variant in driving tumor growth through the NF- $\kappa$ B pathway, akin to mutation of *CYLD*. To further confirm that the p.V1092A *ALPK1* mutation activates NF- $\kappa$ B signalling we performed immunohistochemistry and found p65 staining of *ALPK1* mutant spiradenomas was indistinguishable from staining of *CYLD* mutant cylindromas (**Fig.4c**).

## **Discussion**

The analysis of adnexal tumors in this study yielded several remarkable results. Firstly, we identified a recurrent somatic missense *ALPK1* mutation (p.V1092A) in the kinase domain of this alpha-kinase and demonstrated that this mutation activates NF- $\kappa$ B signalling in cell reporter systems. Importantly, *ALPK1* has previously been suggested to function as an oncogene<sup>45</sup>. Since kinases can be readily inhibited this mutation represents a potential therapeutic target, which might be particularly advantageous in the advanced/metastatic setting, where effective treatments have not been identified. Secondly, we found driver genes not previously associated with adnexal tumors. For example, statistical analyses revealed significant enrichment of mutations in *DNMT3A* in cylindromas, a gene previously linked to haematopoietic malignancies, where it plays a role in the regulation of DNA methylation<sup>46, 47</sup>. Further studies will be required to establish the direct functional role of these mutations in adnexal tumors and their effect on the epigenetic landscape. Mutations in genes such as *AKT1*, *BCOR* and *PIK3R1* were also observed and these

genes may also contribute to tumor development. In keeping with previous studies, we found frequent mutation of the *CYLD* gene<sup>7, 48</sup>. Somatic or germline *CYLD* mutations were found in 12/12 cylindroma patients (matched tumour-germline cases) with mutations also being observed in spiradenoma and high-grade spiradenocarcinoma cases. Notably, these mutations were mutually exclusive from the abovementioned *ALPK1* variant. As the aetiology of adnexal tumors is unknown we performed a mutational signatures analysis. This revealed the presence of signature 1 across all tumor types, which is age-associated, but also the UV-associated signature 7 in cylindromas, presumably because these tumors are generally found on the head and neck. There was also some suggestion of signature 26, associated with mismatch repair, in low-grade spiradenocarcinomas. Tumors in our adnexal collection were not only low in terms of their somatic mutation burden but also appeared to lack significant copy number alterations, the exception being several of the high-grade spiradenocarcinomas which, compared to other adnexal tumors, were replete with copy number gains. Finally, we identified germline variants in *CYLD* that have not been described previously, and thus represent new pathogenic alleles. We also found cases with pathogenic variants in the ClinVar database including in *PTEN* and *NSDI*, suggesting potential adnexal tumor predisposition alleles. The identification of a patient with an *NSDI* mutation, which is associated with Sotos syndrome, is of particular interest since previous case reports suggest adnexal tumors in some patients with this condition<sup>49</sup>. These insights should be explored in larger case series.

In summary, our paper reports the most comprehensive picture of the genomic landscape of adnexal tumors to date, including driver genes, copy number alterations and a potentially actionable kinase mutation and mutational signatures. We hope these studies will help inform the management of patients with these malignancies.

## Methods

### Patients and samples

Samples for whole exome sequencing (WES) and targeted gene panel sequencing (TGPS) were collected from 57 patients and divided into a discovery (tumor/adjacent normal-germline pairs) and a validation cohort (tumor only). The discovery cohort contained 52 tumors/samples and matched adjacent normal/germline DNA from 42 patients. This cohort was used for the initial genomic profiling and driver gene analyses. Mutations from 23 additional samples (15 patients) from the validation cohort were also reported. From some lesions we were able to obtain high-grade and low-grade spiradenocarcinoma regions which were sequenced and analysed separately. A detailed description of each case/sample can be found in **Supplementary Data 1**. All diagnoses were confirmed by two independent pathologists. Ethical approval was obtained from the West Lothian Tissue bank. DNA was extracted using Qiagen kits.

### Whole-exome sequencing

Exonic DNA was captured using the Agilent whole-exome capture kit (SureSelect All Exon V5). Captured material was indexed and sequenced on the Illumina HiSeq2500 platform at the Wellcome Sanger Institute to a median depth of 60x. Raw 75 bp pair-end sequencing reads were aligned with BWA (v0.7.12) to the GRCh37 human reference genome producing a single Binary Alignment Map (BAM) file for each sample<sup>50</sup>. Duplicated reads resulting from PCR were marked with BioBamBam (v2.0.54)<sup>35, 50, 51</sup>.

### Targeted gene panel resequencing

To confirm our findings from whole exome sequencing we validated mutations in the top recurrently mutated genes using panel sequencing (**Supplementary Data 5**). Genomic regions for 550 genes were captured using Agilent custom pulldown baits. Captured material was indexed and sequenced on the Illumina HiSeq4000 platform to a median depth of 117x. Raw 75 bp pair-end sequencing reads were processed using the same pipeline as used for whole-exome sequencing described above.

### Somatic variant detection

Somatic variants were detected using CaVEMan, an expectation maximization-based somatic substitution detection algorithm<sup>52</sup>. To ensure tumor and normal were paired correctly for somatic variant calling and to avoid any possible sample swap we used genotype data from 20,000 randomly selected germline variants. A pairwise correlation coefficient between each sample pair is shown in **Supplementary Fig. 7**. Candidate somatic variants were then filtered for quality and to remove common population variants (ExAC allele frequency > 0.0001). Small insertion and deletion (indel) detection was performed using the cgpPindel

pipeline (v0.2.4w)<sup>53</sup>. Detected indels were then filtered for quality, sequence coverage in both tumor and normal, strand bias, and for overlap with known simple repeats or indels in an in-house normal panel.

### **Variant quality control for FFPE artefacts**

Formalin fixation of tumor biopsies can have a detrimental impact on DNA integrity and introduce C>T/G>A sequencing artefacts<sup>54</sup>. These artefacts are more frequently observed at a 0.01-0.10 mutant allele fraction (MAF)<sup>54</sup>. To remove these variants, we used the following filters:

- Tumor read depth (TRD) and adjacent normal/germline read depth (NRD) greater than or equal to 10.
- Mutation with MAF  $\leq 0.10$  is kept only if TRD and NRD is greater than equal to 30.
- Mutation with MAF  $\leq 0.05$  is kept only if TRD is greater than or equal to 100.

After filtering our somatic point mutation validation rate from the whole exome sequencing data was 82% for SNVs and 73% for indels as confirmed by targeted sequencing.

### **Mutual exclusivity analysis of *ALPK1* and *CYLD* mutations**

Mutual exclusivity between *ALPK1* and *CYLD* was evaluated using the DISCOVER<sup>23</sup> co-occurrence and mutual exclusivity analysis tool. Somatic point mutations and small indels from all 52 tumors were combined into a single  $N \times M$  binary data matrix, where each cell value  $V_{i,j}$  ( $i=1 \dots N$  [Number of genes],  $j=1 \dots M$  [Number of tumors]) indicated the status of gene  $i$  in tumor  $j$ .  $V_{i,j} = 1$  if gene  $i$  is mutated in tumor  $j$  and 0 otherwise. Alteration status of all genes across all tumors was used to generate a null distribution for background alternation rate estimation. Finally, we computed pairwise mutual exclusivity between any two genes mutated in more than two tumors, taking the null distribution in to account.

### **Germline mutation burden analysis**

We applied an exome-wide Fisher's exact test to assess the significance of observing  $n$  mutations in gene  $X$  in our 42 germline samples, given gene  $X$  has a mutation rate of  $Y$  in a control population. To select an appropriate control population, we performed a principal component analysis using 2504 individuals across multiple populations from the 1000 Genomes Project phase3<sup>55</sup>. We randomly selected 2000 single nucleotide polymorphic variants (SNPs) and to mitigate the impact of population specific rare variants we only selected SNPs with a population allele frequency between 0.1 and 0.7. PCA analysis revealed that all 42 patients with tumor-germline pairs were of European descent (**Supplementary Fig. 8**). Therefore, polymorphic variants from the ExAC database from individuals of non-Finnish European descent were

used as a negative control. Readers should be mindful of the strengths and weakness of such an approach<sup>56</sup>. A Combined Annotation Dependent Depletion (CADD) score filter was applied and only variants with a CADD score above or equal to 15 were taken forward for burden testing. We also ensured that only variants with sequence coverage of >10x in both the case and control data set were used. Finally, we applied a Fisher's exact test on every gene to estimate the likelihood of observing  $n$  deleterious mutations given the background mutation rate of that gene in the control population. The Benjamini-Hochberg method was used to correct for multiple testing and only genes with an adjusted  $p$ -value less or equal to 0.05 were reported as significant.

### **Mutational signature analysis**

To reduce the potential impact of artefacts from 5-methylcytosine deamination and degradation in our FFPE samples, low allelic fraction mutations (mutant allele fraction < 0.10 and read depth < 10) were removed from the signature delineation process (as outlined above). Somatic point mutations were then mapped to the 96 possible trinucleotide contexts taking into account the probability of each mutation occurring in each trinucleotide within the human genome. We then applied deconstructSigs, a multiple linear regression-based algorithm to reconstruct the mutation profile of each tumor sample using a linear combination of predefined mutational signatures<sup>32</sup>. Thirty human cancer signatures as defined in Alexandrov *et.al*, were used for the reconstruction and one "unknown" signature<sup>30</sup>.

### **DNA copy number analysis**

To estimate allele-specific copy number profiles we used the Sequenza software package (v2.1.0), a probabilistic model-based algorithm applied to segmented average depth ratio (tumor versus normal) and B allele frequency<sup>34</sup>. Pre-processing and analysis with Sequenza were performed as described in the Sequenza documentation and fitted models were manually examined. For four tumor-normal pairs default fitted model suggested very high ploidy. However, after manual inspection of the depth ratio and B-allele fraction data an alternative solution closer to ploidy 2 was selected due to lack of evidence for high ploidy.

### **Gene fusion analysis by Fluorescence *in situ* Hybridization**

Fusion gene analysis of the paraffin-embedded tissue sections was performed using the *MYB-NFIB* fusion/translocation FISH probe kit from CytoTest, following the manufacturer protocol. The *MYB* 5' probe covers the entire *MYB* gene along with upstream (5') and some downstream (3') genomic sequences. The *NFIB* 3' probe covers the 3' (end) portion of the *NFIB* gene along with some adjacent genomic sequence. An adenoid cystic carcinoma (PD\_ACC) case known to carry the fusion was used as a positive control.

### ***ALPK1* hotspot validation using Sanger sequencing**

DNA was extracted as above for exome sequencing. The region of interest of *ALPK1* was amplified using ThermoFisher Platinum HiFi *Taq* DNA polymerase (following manufacturer's instructions) using the oligos shown below. Amplified products were sequenced by Sanger Sequencing (Eurofins) using the same oligos. Sequence traces were analysed by visual inspection.

*ALPK1* Forward: 5' TTGATCTCCTCTCTTACTCCA 3'

*ALPK1* Reverse: 5' ATGCTAGCCTGATTATGTGGAA 3'

### **Functional analysis of *ALPK1* mutation by NFκB reporter assays**

MCF-7, T-47D, WM266-4, WM1552C, PANC-1 and MIA PaCa-2 cells (obtained from the American Type Culture Collection [ATCC]) were seeded in T25 flasks to obtain 80% confluence for transfection. The following day, cells were transfected with 1.5μg WT or Mut *ALPK1* cDNA and 1.5μg RFP using the Effectene kit (Qiagen), according to the manufacturer's protocol. After 24hr, 4,000 cells were transferred to six wells per line/construct in a 384-well TC-treated PerkinElmer Cell Carrier Ultra plate. After a further 24hr, cells were fixed with formaldehyde/PBS at a final concentration of 4% for 10 min at 37 °C. Cells were permeabilised in 0.2 % TritonX-100/PBS (Sigma Aldrich) for 10 min and blocked in 2 % BSA/PBS for 1 hr at RT. Cells were stained with rabbit anti-p65/RELA NF-κB (Abcam; cat 16502; 1:500) for 2hr at RT then Alexa 647 goat anti-rabbit IgG (Invitrogen, 1:500) for 1hr at RT. Cells were stained with 10μg/ml Hoechst (Sigma Aldrich; cat 33258) for 10 min at RT. Images were taken using the PerkinElmer Opera confocal microscope and a 20x air objective. Image analysis was performed using custom image analysis scripts with PerkinElmer's Columbus 2.6.0 software.

### **MYB expression by immunohistochemistry**

MYB overexpression in cylindromas has been reported in several earlier studies<sup>57</sup>. We attempted to assess MYB expression status in 26 samples (11 cylindromas, 6 spiradenomas and 9 high-grade spiradenocarcinomas) using immunohistochemistry (IHC) (**Supplementary Data 4**). IHC was performed on 4-μm-thick formalin-fixed paraffin-embedded whole-tissue sections following antigen retrieval with Target Retrieval solution (pH 6.1; Dako, Carpinteria, CA, USA) in a pressure cooker using a rabbit monoclonal anti-MYB monoclonal antibody (1:200 dilution; clone EP769Y; Abcam, Cambridge, MA, USA) and the Envision+ polymer detection system (Dako). Immunohistochemistry for p65 was performed using an anti-NF-κB p65 antibody (1:5000 dilution; clone D14E12; Cell Signaling Technology, Danvers, MA, USA) as described for MYB above.



## **Data availability**

The data has been accessioned under the study [EGAS00001001799](https://www.ebi.ac.uk/ena/browser/view/EGAS00001001799) in the European Genome-phenome Archive. Source Data File 1 provides all of the variant calls in MAF and VCF format.

## **Acknowledgements**

This work was supported by grants from Cancer Research UK, the Wellcome Trust and by the ERC Combat Cancer Project to DJA. C.B. is funded by the Stand Up to Cancer campaign for Cancer Research UK and by Cancer Research UK Programme Foundation Award (C37275/ A20146). We also wish to thank Dr. J.W.R. Meijer (Rijnstate Hospital, Arnhem, the Netherlands) on behalf of the PALGA-group and Fengtang Yang for technical assistance.

## **Author contributions**

R.M, M.v.d.H, MJA, TB and DJA designed the study and oversaw the research. M.R, S.C and C.D.R.E performed data analysis. T.M, F.B, I.F, A.R, B.L, Z.M, N.d.S.A, J.K, S.D.B, M.A.D, P.W.H, R.M.P, J.L.H, M.J.A and TB performed histopathological analysis of the tumour samples. A.P, and C.B performed NF- $\kappa$ B assays. J.L.H performed immunohistochemistry on tissue samples. L.v.d.W, J.H and G.C processed tissue samples for sequencing. S.L performed FISH analysis. R.M, MJA, TB and DJA wrote the paper with input from all other authors.

## **Competing Interests**

The authors declare no competing interests.

## References

1. Singh DD, *et al.* Cylindroma of head and neck: review of the literature and report of two rare cases. *J Craniomaxillofac Surg* **41**, 516-521 (2013).
2. Young AL, Kellermayer R, Szigeti R, Teszas A, Azmi S, Celebi JT. CYLD mutations underlie Brooke-Spiegler, familial cylindromatosis, and multiple familial trichoepithelioma syndromes. *Clin Genet* **70**, 246-249 (2006).
3. van der Horst MP, Marusic Z, Hornick JL, Luzar B, Brenn T. Morphologically low-grade spiradenocarcinoma: a clinicopathologic study of 19 cases with emphasis on outcome and MYB expression. *Mod Pathol* **28**, 944-953 (2015).
4. Dai B, Kong YY, Cai X, Shen XX, Kong JC. Spiradenocarcinoma, cylindrocarcinoma and spiradenocylindrocarcinoma: a clinicopathological study of nine cases. *Histopathology* **65**, 658-666 (2014).
5. Granter SR, Seeger K, Calonje E, Busam K, McKee PH. Malignant eccrine spiradenoma (spiradenocarcinoma): a clinicopathologic study of 12 cases. *Am J Dermatopathol* **22**, 97-103 (2000).
6. Kazakov DV, *et al.* Morphologic diversity of malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma based on the study of 24 cases, sporadic or occurring in the setting of Brooke-Spiegler syndrome. *Am J Surg Pathol* **33**, 705-719 (2009).
7. Bignell GR, *et al.* Identification of the familial cylindromatosis tumour-suppressor gene. *Nature genetics* **25**, 160-165 (2000).
8. Fehr A, Kovacs A, Loning T, Frierson H, Jr., van den Oord J, Stenman G. The MYB-NFIB gene fusion-a novel genetic link between adenoid cystic carcinoma and dermal cylindroma. *The Journal of pathology* **224**, 322-327 (2011).
9. Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. *Proc Natl Acad Sci U S A* **106**, 18740-18744 (2009).
10. Kazakov DV, *et al.* Expression of p53 and TP53 mutational analysis in malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma, sporadic or associated with Brooke-Spiegler syndrome. *Am J Dermatopathol* **32**, 215-221 (2010).
11. Biernat W, Peraud A, Wozniak L, Ohgaki H. p53 mutations in sweat gland carcinomas. *International journal of cancer* **76**, 317-320 (1998).

12. Martincorena I, *et al.* Universal Patterns of Selection in Cancer and Somatic Tissues. *Cell* **173**, 1823 (2018).
13. Gundem G, *et al.* IntOGen: integration and data mining of multidimensional oncogenomic data. *Nat Methods* **7**, 92-93 (2010).
14. Martincorena I, *et al.* Universal Patterns of Selection in Cancer and Somatic Tissues. *Cell* **171**, 1029-1041 e1021 (2017).
15. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. *Nucleic Acids Res* **39**, e118 (2011).
16. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. *Nucleic Acids Res* **31**, 3812-3814 (2003).
17. Adzhubei IA, *et al.* A method and server for predicting damaging missense mutations. *Nat Methods* **7**, 248-249 (2010).
18. Liao HF, *et al.* Down-regulated and Commonly mutated ALPK1 in Lung and Colorectal Cancers. *Sci Rep* **6**, 27350 (2016).
19. Ko AM, *et al.* ALPK1 genetic regulation and risk in relation to gout. *Int J Epidemiol* **42**, 466-474 (2013).
20. Wang SJ, *et al.* Lymphocyte alpha-kinase is a gout-susceptible gene involved in monosodium urate monohydrate-induced inflammatory responses. *J Mol Med (Berl)* **89**, 1241-1251 (2011).
21. Chen PK, *et al.* ALPK1 expression is associated with lymph node metastasis and tumor growth in oral squamous cell carcinoma patients. *The American journal of pathology*, (2018).
22. Martincorena I, *et al.* Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. *Science* **348**, 880-886 (2015).
23. Canisius S, Martens JW, Wessels LF. A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence. *Genome biology* **17**, 261 (2016).
24. Curtius K, Wright NA, Graham TA. An evolutionary perspective on field cancerization. *Nature reviews Cancer* **18**, 19-32 (2018).

25. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. *Nature* **424**, 801-805 (2003).
26. Alameda JP, *et al.* An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells. *Oncogene* **29**, 6522-6532 (2010).
27. Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. *Cell Death Differ* **17**, 25-34 (2010).
28. Mather CA, *et al.* CADD score has limited clinical validity for the identification of pathogenic variants in noncoding regions in a hereditary cancer panel. *Genet Med* **18**, 1269-1275 (2016).
29. Horn S, *et al.* TERT promoter mutations in familial and sporadic melanoma. *Science (New York, NY)* **339**, 959-961 (2013).
30. Alexandrov LB, *et al.* Signatures of mutational processes in human cancer. *Nature* **500**, 415-421 (2013).
31. Nik-Zainal S, *et al.* Mutational processes molding the genomes of 21 breast cancers. *Cell* **149**, 979-993 (2012).
32. Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. *Genome biology* **17**, 31 (2016).
33. Alexandrov LB, *et al.* Clock-like mutational processes in human somatic cells. *Nature genetics* **47**, 1402-1407 (2015).
34. Favero F, *et al.* Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. *Annals of oncology : official journal of the European Society for Medical Oncology* **26**, 64-70 (2015).
35. Li H, *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics (Oxford, England)* **25**, 2078-2079 (2009).
36. Lek M, *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285-291 (2016).
37. Katoh M. Function and cancer genomics of FAT family genes (review). *Int J Oncol* **41**, 1913-1918 (2012).

38. Mahoney PA, Weber U, Onofrechuk P, Biessmann H, Bryant PJ, Goodman CS. The fat tumor suppressor gene in *Drosophila* encodes a novel member of the cadherin gene superfamily. *Cell* **67**, 853-868 (1991).
39. Cappello S, *et al.* Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development. *Nat Genet* **45**, 1300-1308 (2013).
40. Ivanovski I, *et al.* Van Maldergem syndrome and Hennekam syndrome: Further delineation of allelic phenotypes. *Am J Med Genet A* **176**, 1166-1174 (2018).
41. Sebio A, *et al.* Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer. *Pharmacogenomics J* **16**, 312-319 (2016).
42. Roth W, *et al.* Bifunctional apoptosis inhibitor (BAR) protects neurons from diverse cell death pathways. *Cell Death Differ* **10**, 1178-1187 (2003).
43. Rio M, *et al.* Spectrum of NSD1 mutations in Sotos and Weaver syndromes. *Journal of medical genetics* **40**, 436-440 (2003).
44. Ha K, *et al.* Steric Clash in the SET Domain of Histone Methyltransferase NSD1 as a Cause of Sotos Syndrome and Its Genetic Heterogeneity in a Brazilian Cohort. *Genes* **7**, (2016).
45. Strietz J, *et al.* ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer. *Oncotarget* **7**, 83278-83293 (2016).
46. Feng J, *et al.* Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. *Nat Neurosci* **13**, 423-430 (2010).
47. Guillaumot M, Cimmino L, Aifantis I. The Impact of DNA Methylation in Hematopoietic Malignancies. *Trends Cancer* **2**, 70-83 (2016).
48. van der Horst MPJ, Brenn T. Update on Malignant Sweat Gland Tumors. *Surgical pathology clinics* **10**, 383-397 (2017).
49. Gilaberte Y, Ferrer-Lozano M, Olivan MJ, Coscojuela C, Abascal M, Lapunzina P. Multiple giant pilomatricoma in familial Sotos syndrome. *Pediatr Dermatol* **25**, 122-125 (2008).
50. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics (Oxford, England)* **25**, 1754-1760 (2009).
51. Tischler G LS. biobambam: tools for read pair collation based algorithms on BAM files. . *Source Code for Biology and Medicine* **9**, ( 2014).

52. David Jones KMR, Helen Davies, Patrick S. Tarpey, Adam P. Butler, Jon W. Teague, Serena Nik-Zainal, Peter J. Campbell. cgpCaVEManWrapper: Simple Execution of CaVEMan in Order to Detect Somatic Single Nucleotide Variants in NGS Data. *Current Protocols in Bioinformatics*, (2016).
53. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. *Bioinformatics (Oxford, England)* **25**, 2865-2871 (2009).
54. Wong SQ, *et al.* Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. *BMC Med Genomics* **7**, 23 (2014).
55. Abecasis GR, *et al.* A map of human genome variation from population-scale sequencing. *Nature* **467**, 1061-1073 (2010).
56. Guo MH, Plummer L, Chan YM, Hirschhorn JN, Lippincott MF. Burden Testing of Rare Variants Identified through Exome Sequencing via Publicly Available Control Data. *American journal of human genetics* **103**, 522-534 (2018).
57. Rajan N, *et al.* Overexpression of MYB drives proliferation of CYLD-defective cylindroma cells. *The Journal of pathology* **239**, 197-205 (2016).

## Legends to Figures

**Fig. 1: The driver gene landscape of adnexal tumors.** Genetic data for the 52 cases where matched tumor/normal DNA sequencing data was available. Additional cases are shown in **Supplementary Fig. 5**. The germline and somatic mutations in this plot were validated by high-depth targeted exome sequencing. Only mutations in coding regions are shown except for *TERT* promoter variants and the splice region mutation in *CYLD*. Please note PD30271 and PD29730 are the same patient who had multiple tumors analysed.

**Fig. 2: Mutations identified in *CYLD* and *ALPK1*.** Variants in *CYLD* (A) and *ALPK1* (B) against the translation of the longest transcript of these genes (ENST00000458497.5 & ENST00000311559.13). Protein domains are from UniProt. All of the variants shown were validated by high-depth targeted exome sequencing. Adjacent normal represents morphologically normal tissue from the same block as the tumor which was used as a germline sample for somatic variant calling. Variants in red were called somatically. Variants in green were called from the adjacent normal tissue. The color of the circles indicate tumor/tissue type. The somatic splice region mutation in PD29703a in *CYLD* is not shown. C. Protein alignment of *ALPK1* across vertebrates. The conservation score represents constrained elements in multiple alignments by quantifying substitution deficits. The arrow indicates the position of the p.V1092 residue in humans.

**Fig. 3: The somatic genetic landscape of adnexal tumors.** A). The contribution of published mutational signatures in adnexal tumors detected using deconstructSigs<sup>32</sup>. Total contribution per sample adds up to one. For this analysis we used all variants including those in non-coding regions such as 5' and 3' UTRs. B). The copy number landscape of adnexal tumors. This analysis was performed using Sequenza to define the absolute copy number for chromosomal segments. These analyses were performed using the tumors shown in **Fig. 1**.

**Fig. 4: Assessment of the *MYB-NFIB* fusion and p65 expression in adnexal tumors.** A). Fluorescence *in situ* hybridization (FISH) imaging of the *MYB-NFIB* fusion in an adenoid cystic carcinoma and assessment in cylindroma samples. Previous reports have suggested that adnexal tumors such as cylindromas carry *MYB-NFIB* fusions which have been associated with *MYB* overexpression<sup>8</sup>. *Left panel* shows an adenoid cystic carcinoma, which is positive control for the fusion event. Yellow signal results from the overlap of the green *NFIB* probe and red *MYB* probe. *Right panel*: a representative cylindroma which was fusion negative. B). Representative histopathological images of a cylindroma at 100x magnification, spiradenoma at 100x magnification, high-grade spiradenocarcinoma at 200x magnification and a low-grade

spiradenocarcinoma at 200x magnification. C). p65 immunohistochemistry of a *CYLD* mutant cylindroma (left) and an *ALPK1* p.V1092A mutant spiradenoma (right) at 20x magnification.